Search

New phage therapy center: The ‘Center for Phage Biology and Therapy at Yale’ has been formally launched at Yale University to advance phage biology understanding, translate advancements into the clinic and provide training & education. Chec

Minireview: Considerations for the use of phage therapy in clinical practice, by Gina Suh et al., on behalf of the Antibacterial Resistance Leadership Group.

Paper: Assessment of the microbiome during bacteriophage therapy in combination with systemic antibiotics to treat a case of staphylococcal device infection, by Andre Mu et al.

Paper: Degradation of host translational machinery drives tRNA acquisition in viruses, by Joy Y. Yang et al.

Paper: Phage co-transport with hyphal-riding bacteria fuels bacterial invasion in a water-unsaturated microbial model system, by Xin You et al.

The first ESGNTA Online Course titled: “Personalised Phage Therapy: Basic Principles of Monitoring and Treatment”, will take place virtually on the 7-10th of June 2022. It will include four sessions with cutting-edge scientific talks in th

The first ESGNTA Online Course titled: “Personalised Phage Therapy: Basic Principles of Monitoring and Treatment”, will take place virtually on the 7-10th of June 2022. It will include four sessions with cutting-edge scientific talks in th

The first ESGNTA Online Course titled: “Personalised Phage Therapy: Basic Principles of Monitoring and Treatment”, will take place virtually on the 7-10th of June 2022. It will include four sessions with cutting-edge scientific talks in th

Thanks to all who came out to the first iVoM Season 2 event of 2022! Next: Feb 2 from 2-3 PM CET Topic: Phage application in the One Health approach. Speakers: Dr. Cath Rees, Prof. Mariana Piuri, Prof. Lone Brøndsted. If you want to join

Hi, I'm looking for a Staph aureus phage that is either phage K or a close relative. I want to use this in my animal model of diabetic foot ulcer infection. I'm at Flinders University in Australia. Thanks. Peter Speck (peter.speck@flinders.

Clinical trial approval: Pherecydes Pharma obtains ANSM Approval for its PhagoDAIR program, which treats osteoarticular infections of prosthetic joints caused by Staphylococcus aureus.

ACD Pharma is constructing a large-scale phage production plant.

Paper: Staphylococcal phages adapt to new hosts by extensive attachment site variability — Helena Leinweber et al.

Paper: A new sugar for an old phage: a c-di-GMP-dependent polysaccharide pathway sensitizes Escherichia coli for bacteriophage infection — Benjamin Sellner et al.

Paper: Isolation and characterization of Campylobacter jejuni–specific bacteriophages from Germany and their suitability for use in food production — Severin Michael Steffan et al.

CDC has some AMAZING new interactive visualizations for Antibiotic Resistance by species, geography, and indication. Great for educating people on how big the problem is. Check it out! — Contributed by Natalie Ma via Twitter

In an effort to help companies navigate the development of their bacteriophage product, IHMA’s VP Global Microbiology Services & CSO, Daniel Sahm has compiled a summary of key considerations to address prior to beginning clinical trials.

Thanks to all who came out to the first iVoM Season 2 event of 2022! Next: Feb 2 from 2-3 PM CET Topic: Phage application in the One Health approach. Speakers: Dr. Cath Rees, Prof. Mariana Piuri, Prof. Lone Brøndsted. If you want to join

IPATH invites the phage therapy community to the virtual screening and discussion event for the new documentary, Salt in My Soul. This film recounts the struggles and feelings of Mallory Smith, who lost her battle with cystic fibrosis and a